The deal includes Nines' data pipeline, machine learning engines, analytics tools, and two U.S. Food and Drug Administration-cleared products. 

The study used non-contrast CT and CT perfusion imaging to analyze agreement between an automated reader and human radiologists with differing experience levels.

The financing was led by Concord Health Partners in conjunction with AlbaCore Capital Group and London-based Hambro Perks.

“Formidable legal obstacles threaten AI’s impact on the specialty and, if unchanged, have the potential to preclude the future success of this emerging industry,” experts cautioned in AJR.

Hedge fund investors and the Redwood City, California, vendor considered adjusting the sale price, but opted to terminate the deal instead.

“In the end, no matter how smart the machines are with their algorithms and mysterious black boxes, they are no match for human virtue when it comes to preserving patient trust and the survival of the profession,” one expert said in AJR.

With up to 30% of breast cancers developing in between screenings, there is a great need to improve risk assessments, experts discussed recently in Radiology.

The artificial intelligence-powered product could prove valuable during neonatal and pediatric exams, leaders said.